BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05935085 (ANB032 in Atopic Dermatitis): BVCT ex-ante prediction vs. reported outcome

On 30 Aug 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 11 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05935085
Acronym
ARISE-AD
Drug Name
ANB032
Drug MoA
anti-BTLA mAb agonist
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Atopic Dermatitis
Human Patients
160
Sponsor
AnaptysBio
Phase
Phase 2

Prediction of , index 1387

Prospective Prediction
Prediction Index
1387
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in EASI75 non-superior to dupilumab inferior to upadacitinib/NM26)
Technical Prediction
partial SUCCESS (statistically significant yet weak clinical benefit in EASI75)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
103 days in advance
Readout Data Interpretation
ANB032 failed to achieve achieved statistical significance in placebo-adjusted EASI75 at week 14
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
Phase
Phase 2
Status
Terminated
Enrollment
201
Lead sponsor
AnaptysBio, Inc.
Conditions
Atopic Dermatitis Eczema
Interventions
DRUG: ANB032; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-06-13
Primary completion
2024-10-16
Completion
2025-01-07
Primary outcomes
  • Proportion of subjects who achieve ≥75% reduction (improvement) from Baseline in EASI-75 as Week 14 (Baseline to Week 14)

NCT05935085 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials